Jeffrey Slovin
CIK 1181235 · View on SEC EDGAR ↗
First SEC filing: Jan. 17, 2017 · Latest: Jan. 17, 2017
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| July 14, 2017 | XRAY | A | 205 | — | — | 766,813 Direct | +0.03% | Acquired | (price as of 2026-08-21) |
| April 14, 2017 | XRAY | A | 212 | — | — | 766,608 Direct | +0.03% | Acquired | (price as of 2026-08-21) |
| March 22, 2017 | XRAY | A | 1,413 | $60.85 | $85,981 | 1,413 Direct | — | Acquired | -82.2% (price as of 2026-08-21) |
| Feb. 22, 2017 | XRAY | A | 23,171 | — | — | 766,396 Direct | +3.12% | Acquired | (price as of 2026-08-21) |
| Feb. 22, 2017 | XRAY | A | 119,600 | — | — | 119,600 Direct | — | Acquired | (price as of 2026-08-21) |
| Feb. 20, 2017 | XRAY | F | 2,027 | $62.68 | $127,052 | 743,225 Direct | -0.27% | Disposed | -82.7% (price as of 2026-08-21) |
| Jan. 13, 2017 | XRAY | A | 179 | — | — | 745,252 Direct | +0.02% | Acquired | (price as of 2026-08-21) |
| Nov. 25, 2016 | XRAY | F | 42,858 | $60.75 | $2,603,624 | 745,073 Direct | -5.44% | Disposed | -82.1% (price as of 2026-08-21) |
| Nov. 20, 2016 | XRAY | F | 2,624 | $60.16 | $157,860 | 787,931 Direct | -0.33% | Disposed | -82.0% (price as of 2026-08-21) |
| Oct. 14, 2016 | XRAY | A | 284 | — | — | 790,555 Direct | +0.04% | Acquired | (price as of 2026-08-21) |
| April 8, 2016 | XRAY | A | 203 | — | — | 203 Direct | — | Acquired | (price as of 2026-08-21) |
| April 8, 2016 | XRAY | A | 121 | — | — | 121 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 22, 2017 | XRAY | Phantom Stock(Supplemental Executive Retirement Plan)(SERP) | Common Stock (1,413) | — | — | 1,413 | Acquired |
| Feb. 22, 2017 | XRAY | Stock Option (Right to Buy) | Common Stock (119,600) | $62.34 | Feb. 22, 2027 | 119,600 | Acquired |
| April 8, 2016 | XRAY | PSU (Performance Stock Unit) | Common Stock (203) | — | — | 203 | Acquired |
| April 8, 2016 | XRAY | RSU (Restricted Stock Unit) | Common Stock (121) | — | — | 121 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2017 | $727,616 | — | — | — | $385,000 | — | $1,506,511 | $7,798,156 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.